Please read Dr. Kumar’s article in Advanced Therapeutics titled, “Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus.“
Diabetes Mellitus (DM) is characterized by pancreatic β-cells insufficiency in either inadequate synthesis and release of insulin (type 1, T1D) or target cells/tissue becoming resistant to glucose uptake driven by insulin (type 2, T2D). Insulin plays a pivotal role in glucose homeostasis by lowering elevated blood glucose to homeostatic levels via stimulating cellular glucose intake in adipose tissue and skeletal muscle fibers and promoting glycogenesis in the liver. However, in diabetics, this dysregulation of insulin-to-glucagon ratio leads to hyperglycemia and advanced-glycation end products that significantly contribute to cardiovascular and renal complications. To read the full article.
Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus. Azizogli AR, Vitti MR, Mishra R, Osorno L, Heffernan C, Kumar VA. Therap. 2023, 2300143. DOI: 10.1002/adtp.202300143